A Multicenter, Randomized, Open-label Phase II Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab for First-line Treatment of Advanced Hepatocellular Carcinoma
Latest Information Update: 19 Dec 2024
At a glance
- Drugs Bevacizumab (Primary) ; Nilvanstomig (Primary) ; Sintilimab (Primary)
- Indications Carcinoma; Liver cancer
- Focus Therapeutic Use
- Sponsors Suzhou Zelgen Biopharmaceuticals
Most Recent Events
- 16 Dec 2024 Status changed from not yet recruiting to recruiting.
- 21 Aug 2024 New trial record